|
Market Closed -
Nasdaq
16:00:00 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 2.950 USD | +13.46% |
|
+17.53% | +43.90% |
| 10-08 | Editas Medicine Shares Rise After Australia Clears Phase 1/2 Trial of EDIT-401 | MT |
| 10-08 | Wells Fargo Upgrades Editas Medicine to Overweight From Equal Weight, $6 Price Target | MT |
| Market Cap | 453M 406M 376M 340M 636M 43.15B 644M 4.49B 1.79B 22.58B 1.7B 1.66B 71.68B | P/E 2026 * |
-3.76x | P/E 2027 * | -4.09x |
|---|---|---|---|---|---|
| Enterprise Value | 316M 284M 262M 238M 444M 30.14B 450M 3.14B 1.25B 15.77B 1.19B 1.16B 50.07B | EV / Sales 2026 * |
12.3x | EV / Sales 2027 * | 16.2x |
| Free-Float |
99.82% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| EDIT | Delayed | |
CBOE
| EDIT | Real-time | |
|
Tradegate
| 8EM | Real-time | |
|
Berne S.E.
| 8EM | End-of-day quote | |
|
Boerse Muenchen
| 8EM | Real-time | |
|
Deutsche Boerse AG
| 8EM | Delayed | |
|
Börse Stuttgart
| 8EM | Delayed |
Last Transcript: Editas Medicine, Inc.
| 1 day | +13.46% | ||
| 1 week | +17.53% | ||
| Current month | +14.79% | ||
| 1 month | +17.53% | ||
| 3 months | +12.60% | ||
| 6 months | -3.59% | ||
| Current year | +43.90% |
| 1 week | 2.3 |  | 2.96 |
| 1 month | 2.24 | | 2.97 |
| Current year | 1.66 | | 3.94 |
| 1 year | 1.66 | | 3.94 |
| 3 years | 0.91 | | 11.69 |
| 5 years | 0.91 | | 42.11 |
| 10 years | 0.91 | | 99.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilmore O’Neill
CEO | Chief Executive Officer | 61 | 2022-05-31 |
Amy Parison
DFI | Director of Finance/CFO | 40 | 2025-03-27 |
Daniel Ory
CTO | Chief Tech/Sci/R&D Officer | - | 2026-09-07 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Hirsch
BRD | Director/Board Member | 55 | 2017-05-29 |
Jessica Hopfield
CHM | Chairman | 61 | 2024-12-30 |
David Scadden
BRD | Director/Board Member | 73 | 2019-02-05 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/8/26 | Free | Chief Technology Officer | 950,000 | 0.6186% | ||
| 9/3/26 | Sell | Chief Financial Officer | -453 | 0.0003% | ||
| 9/3/26 | Sell | Chief Executive Officer | -5,124 | 0.0033% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +13.46% | +17.53% | -6.94% | -52.88% | 399M | |
| +0.65% | -3.36% | +36.98% | +60.50% | 63.48B | |
| +1.76% | +1.27% | +11.82% | +81.21% | 54.55B | |
| -0.94% | +0.99% | +10.45% | +100.19% | 53.59B | |
| +2.76% | +0.87% | +27.92% | +55.07% | 44.75B | |
| +2.00% | -3.39% | +17.83% | +119.04% | 41.62B | |
| +1.34% | -2.86% | +224.43% | +914.08% | 39.91B | |
| +0.64% | -3.95% | +11.15% | +45.57% | 32.47B | |
| +29.06% | +47.63% | +107.12% | +92.73% | 26.7B | |
| +3.72% | -6.23% | +26.01% | -2.99% | 23.36B | |
| Average | +5.45% | -0.30% | +46.68% | +141.25% | 38.08B | |
| Weighted average by Cap. | +3.25% | -0.29% | +48.13% | +161.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 25.79M 23.14M 21.4M 19.38M 36.2M 2.46B 36.64M 256M 102M 1.29B 96.8M 94.75M 4.08B | 19.46M 17.46M 16.14M 14.62M 27.31M 1.85B 27.64M 193M 76.87M 970M 73.02M 71.48M 3.08B |
| Net income | -95.2M -85.41M -78.97M -71.52M -134M -9.07B -135M -944M -376M -4.74B -357M -350M -15.06B | -121M -108M -100M -90.69M -169M -11.5B -171M -1.2B -477M -6.02B -453M -443M -19.1B |
| Net Debt | -137M -123M -113M -103M -192M -13.01B -194M -1.35B -540M -6.81B -513M -502M -21.62B | -138M -123M -114M -103M -193M -13.1B -195M -1.36B -543M -6.86B -516M -505M -21.76B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-28 | US$2.950 | +13.46% | 4,427,620 |
| 26-10-27 | US$2.600 | +8.33% | 3,079,366 |
| 26-10-26 | US$2.400 | 0.00% | 1,350,904 |
| 26-10-23 | US$2.400 | -3.61% | 1,313,712 |
| 26-10-22 | US$2.490 | -0.80% | 1,066,486 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- EDIT Stock
Select your edition
All financial news and data tailored to specific country editions
